Emerging consensus supports distinction of treatment strategies from those typically used for relapsing remitting MS, and several groups debate whether to follow treatment protocols akin to those for AQP4-Ab NMOSD [14, 15]. The gene discussed is AQP4; the disease is relapsing-remitting multiple sclerosis.